Ohcanbohtosat - Isabelle Dussault
- Čájehuvvo 1 - 13 / 13
-
1
-
2
-
3
-
4
-
5
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort Dahkki Benjamin Tan, Adnan Khattak, Enriqueta Felip, Karen Kelly, Patricia Rich, Ding Wang, Christoph Helwig, Isabelle Dussault, Laureen S. Ojalvo, Nicolás Isambert
Almmustuhtton 2021Artigo -
6
-
7
Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment Dahkki James L. Gulley, Jeffrey Schlom, Mary Helen Barcellos‐Hoff, Xiao‐Jing Wang, Joan Seoane, François Audhuy, Yan Lan, Isabelle Dussault, Aristidis Moustakas
Almmustuhtton 2021Revisão -
8
-
9
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer Dahkki Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, Masatoshi Kudo, Makoto Ueno, Shunsuke Kondo, Li-Tzong Chen, Motonobu Osada, Christoph Helwig, Isabelle Dussault, Masafumi Ikeda
Almmustuhtton 2020Artigo -
10
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial Dahkki Luis Paz‐Ares, Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Ki Hyeong Lee, Chia‐Chi Lin, M.J. Flor, Massimo Di Nicola, Rosa Álvarez, Isabelle Dussault, Christoph Helwig, Laureen S. Ojalvo, James L. Gulley, Byoung Chul Cho
Almmustuhtton 2020Artigo -
11
<i>In Vitro</i> and <i>In Vivo</i> Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models Dahkki Paul E. Hughes, Karen Rex, Sean Caenepeel, Yajing Yang, Yihong Zhang, Martin A. Broome, Hue T. Kha, Teresa L. Burgess, Benny Amore, Paula Kaplan‐Lefko, Jodi Moriguchi, Jonathan Werner, Michael A. Damore, D. N. Baker, Deborah M. Choquette, Jean-Christophe Harmange, Robert Radinsky, Richard Kendall, Isabelle Dussault, Angela Coxon
Almmustuhtton 2016Artigo -
12
Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines Dahkki Marc Payton, Tammy L. Bush, Grace Chung, Beth Ziegler, Patrick Eden, Patricia McElroy, Sandra L. Ross, Victor J. Cee, Holly L. Deak, Brian L. Hodous, Hanh Nho Nguyen, Philip R. Olivieri, Karina Romero, Laurie B. Schenkel, Annette Bak, Mary K. Stanton, Isabelle Dussault, Vinod F. Patel, Stephanie Geuns-Meyer, Robert Radinsky, Richard Kendall
Almmustuhtton 2010Artigo -
13
STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells Dahkki Carol Babij, Yihong Zhang, Robert J. Kurzeja, Anke Munzli, Amro Shehabeldin, Manory Fernando, Kim Quon, Paul D. Kassner, Astrid Ruefli-Brasse, Vivienne J. Watson, Flordeliza Fajardo, Angela Jackson, James Zondlo, Yu Sun, Aaron R. Ellison, Cherylene A. Plewa, Miguel Tisha San, John H. Robinson, John D. McCarter, Ralf Schwandner, Ted Judd, Josette Carnahan, Isabelle Dussault
Almmustuhtton 2011Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Biology
Cell biology
Gene
Biochemistry
Genetics
Medicine
Nuclear receptor
Transcription factor
Internal medicine
Pharmacology
Cancer
Cancer research
Chemistry
Oncology
Receptor
Adverse effect
Clinical endpoint
Clinical trial
Constitutive androstane receptor
Gastroenterology
Kinase
Ligand (biochemistry)
Response Evaluation Criteria in Solid Tumors
Agonist
Androstane
Biophysics
Cell culture
Cell growth
Enzyme
Phases of clinical research